Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MIF | P14174 | 3/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | ZDHHC7 | Q9NXF8 | 1/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | MGAM | O43451 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | SI | P14410 | 1/20 | 0.30 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10201901 | 1.00 | MIF (0.42) | MIFCA1CA2SMN1; SMN2ZDHHC7 | |
| SCHEMBL10695428 | 0.88 | CA2 (0.50) | MIFCA1CA2ZDHHC7MAPT | |
| SCHEMBL27212164 | 0.84 | CA1 (0.40) | MIFCA1CA2SMN1; SMN2ZDHHC7 | |
| SCHEMBL404232 | 0.83 | MIF (0.34) | MIFCA1CA2SMN1; SMN2CA12 | |
| SCHEMBL5118852 | 0.83 | ALDH1A1 (0.37) | HSD17B10TSHRMGAMGAASI | |
| SCHEMBL16542988 | 0.82 | MIF (0.30) | MIF | |
| SCHEMBL7872869 | 0.82 | CA1 (0.36) | MIFCA1CA2ZDHHC7 | |
| SCHEMBL23423085 | 0.82 | ZDHHC7 (0.39) | MIFCA1CA2SMN1; SMN2ZDHHC7 | |
| SCHEMBL5724792 | 0.82 | MIF (0.41) | MIFCA1CA2SMN1; SMN2ZDHHC7 | |
| SCHEMBL21707116 | 0.82 | CA1 (0.37) | MIFCA1CA2SMN1; SMN2ZDHHC7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9809822-B2 | Triptolide derivatives and preparation method and use thereof | HONG KONG BAPTIST UNIVERSITY (HK) | 2017-11-07 | — | — | US | claimed |
| US-9809822-B2 | Triptolide derivatives and preparation method and use thereof | HONG KONG BAPTIST UNIVERSITY (HK) | 2017-11-07 | — | — | US | disclosed |
| US-20160362691-A1 | TRIPTOLIDE DERIVATIVES AND PREPARATION METHOD AND USE THEREOF | HONG KONG BAPTIST UNIVERSITY (HK) | 2016-12-15 | — | — | US | disclosed |
| US-20150216989-A1 | MULTI-DAY DELIVERY OF BIOLOGICALLY ACTIVE SUBSTANCES | SAMOS PHARMACEUTICALS, INC. (US) | 2015-08-06 | — | — | US | disclosed |
| US-8992977-B2 | Multi-day delivery of biologically active substances | SAMOS PHARMACEUTICALS, LLC (US) | 2015-03-31 | — | — | US | disclosed |
| US-20140142199-A1 | ABSORBABLE BRANCHED POLYESTERS AND POLYURETHANES | BEZWADA BIOMEDICAL, LLC | 2014-05-22 | — | — | US | disclosed |
| US-20140142199-A1 | ABSORBABLE BRANCHED POLYESTERS AND POLYURETHANES | BEZWADA BIOMEDICAL, LLC | 2014-05-22 | — | — | US | disclosed |
| US-20110046599-A1 | Multi-Day Delivery Of Biologically Active Substances | SAMOS PHARMACEUTICALS LLC | 2011-02-24 | — | — | US | disclosed |
| EP-2170376-A1 | MULTI-DAY DELIVERY OF BIOLOGICALLY ACTIVE SUBSTANCES | Samos Pharmaceuticals, Llc (US) | 2010-04-07 | — | — | EP | disclosed |
| WO-2009002542-A1 | MULTI-DAY DELIVERY OF BIOLOGICALLY ACTIVE SUBSTANCES | SAMOS PHARMACEUTICALS, LLC (US) | 2008-12-31 | — | — | WO | disclosed |
| US-4871864-A | Carbamoyloxythiophene fungicides | BAYER AKTIENGESELLSCHAFT (DE) | 1989-10-03 | — | — | US | disclosed |
| US-4863954-A | Acyloxythiophene-carboxamide fungicides | BAYER AKTIENGESELLSCHAFT (DE) | 1989-09-05 | — | — | US | disclosed |
| US-4839381-A | FUNGICIDES, PESTICIDES; RICE PLANTS | BAYER AKTIENGESELLSCHAFT (DE) | 1989-06-13 | — | — | US | disclosed |
| US-4767757-A | Acyloxythiophene-carboxamide fungicides, compositions and use | BAYER AKTIENGESELLSCHAFT (DE) | 1988-08-30 | — | — | US | disclosed |
| EP-0243776-A2 | Carbamoyloxythiophene derivatives | BAYER AG (DE) | 1987-11-04 | — | — | EP | disclosed |
| EP-0241735-A2 | Acyloxythiophene carbon amide | BAYER AG (DE) | 1987-10-21 | — | — | EP | disclosed |
| EP-0000023-B1 | OMEGA-SUBSTITUTED PENTYL UREAS, THEIR PREPARATION AND THEIR USE AS FUNGICIDES | BAYER AG (DE) | 1980-07-23 | — | — | EP | disclosed |
| US-4188401-A | Combating fungi with 1-(ω-substituted pentyl)-3-(2-cyano-acetyl)-ureas | BAYER AKTIENGESELLSCHAFT (DE) | 1980-02-12 | — | — | US | disclosed |
| EP-0000023-A1 | Omega-substituted pentyl ureas, their preparation and their use as fungicides | BAYER AG (DE) | 1978-12-20 | — | — | EP | disclosed |
| US-4079147-A | Fungicidally active derivatives of carbamic acid oxime-esters of isonitrosocyanoacetic acid | BAYER AKTIENGESELLSCHAFT (DT) | 1978-03-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110046599-A1 | Multi-Day Delivery Of Biologically Active Substances | GUSB, SERPINA6, CD44 | MIF 145/4885CA1 1123/4885CA2 2803/4885 |
| US-20150216989-A1 | MULTI-DAY DELIVERY OF BIOLOGICALLY ACTIVE SUBSTANCES | GUSB, SERPINA6, CD44 | MIF 145/4885CA1 1123/4885CA2 2803/4885 |
| US-20160362691-A1 | TRIPTOLIDE DERIVATIVES AND PREPARATION METHOD AND USE THEREOF | TPD52L2, TRDMT1, MCTS1 | MIF 1091/4885CA1 1962/4885CA2 2109/4885 |
| US-20140142199-A1 | ABSORBABLE BRANCHED POLYESTERS AND POLYURETHANES | SI, MGAM, BPHL | MIF 264/4885CA1 2642/4885CA2 2860/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.